CA2671302A1 - Genes et voies regules par miarn comme cibles d'intervention therapeutique - Google Patents

Genes et voies regules par miarn comme cibles d'intervention therapeutique Download PDF

Info

Publication number
CA2671302A1
CA2671302A1 CA002671302A CA2671302A CA2671302A1 CA 2671302 A1 CA2671302 A1 CA 2671302A1 CA 002671302 A CA002671302 A CA 002671302A CA 2671302 A CA2671302 A CA 2671302A CA 2671302 A1 CA2671302 A1 CA 2671302A1
Authority
CA
Canada
Prior art keywords
nucleic acid
cell
mir
mirna
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002671302A
Other languages
English (en)
Inventor
Mike Byrom
Charles D. Johnson
David Brown
Andreas G. Bader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Asuragen Inc
Original Assignee
Asuragen, Inc.
Yale University
Mike Byrom
Charles D. Johnson
David Brown
Andreas G. Bader
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asuragen, Inc., Yale University, Mike Byrom, Charles D. Johnson, David Brown, Andreas G. Bader filed Critical Asuragen, Inc.
Publication of CA2671302A1 publication Critical patent/CA2671302A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
CA002671302A 2006-12-08 2007-12-10 Genes et voies regules par miarn comme cibles d'intervention therapeutique Abandoned CA2671302A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86929506P 2006-12-08 2006-12-08
US60/869,295 2006-12-08
US88275806P 2006-12-29 2006-12-29
US60/882,758 2006-12-29
PCT/US2007/087038 WO2008073923A2 (fr) 2006-12-08 2007-12-10 Gènes et voies régulés par miarn comme cibles d'intervention thérapeutique

Publications (1)

Publication Number Publication Date
CA2671302A1 true CA2671302A1 (fr) 2008-06-19

Family

ID=39512449

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002671302A Abandoned CA2671302A1 (fr) 2006-12-08 2007-12-10 Genes et voies regules par miarn comme cibles d'intervention therapeutique

Country Status (5)

Country Link
EP (2) EP2102341A2 (fr)
AU (2) AU2007333110A1 (fr)
CA (1) CA2671302A1 (fr)
IL (1) IL199161A0 (fr)
WO (2) WO2008073923A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111972399A (zh) * 2020-08-06 2020-11-24 温州医科大学 维持肝细胞活性的保存液

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542501T3 (es) 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
US8513209B2 (en) 2007-11-09 2013-08-20 The Board Of Regents, The University Of Texas System Micro-RNAS of the MIR-15 family modulate cardiomyocyte survival and cardiac repair
ES2397672T3 (es) 2007-12-05 2013-03-08 The Wistar Institute Of Anatomy And Biology Método de diagnóstico de cánceres de pulmón utilizando perfiles de expresión genética en células mononucleares de sangre periférica
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP2010094122A (ja) * 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
US9068974B2 (en) 2008-11-08 2015-06-30 The Wistar Institute Of Anatomy And Biology Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
ES2562832T3 (es) 2009-12-08 2016-03-08 Abbvie Deutschland Gmbh & Co Kg Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
LT2807192T (lt) 2012-01-27 2018-07-25 AbbVie Deutschland GmbH & Co. KG Kompozicijos ir būdai, skirti ligų, susijusių su neuritų degeneracija, diagnostikai ir gydymui
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
WO2017005773A1 (fr) * 2015-07-07 2017-01-12 Universite de Bordeaux Utilisation de micro-arn ciblant la bêta-caténine pour le traitement du cancer du foie
US11692226B2 (en) 2017-07-31 2023-07-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Genotyping of SNPs to stratify cancer risk
EP3795585A4 (fr) * 2018-05-16 2022-03-16 Genome and Company Composition pharmaceutique destinée à prévenir ou traiter le cancer comprenant un inhibiteur de lrit2 en tant que principe actif

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504605C (fr) * 2002-11-13 2016-01-19 Thomas Jefferson University Compositions et procedes de diagnostic et de therapie du cancer
CN101296702B (zh) * 2005-09-12 2012-11-28 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111972399A (zh) * 2020-08-06 2020-11-24 温州医科大学 维持肝细胞活性的保存液
CN111972399B (zh) * 2020-08-06 2021-11-30 温州医科大学 维持肝细胞活性的保存液

Also Published As

Publication number Publication date
WO2008085797A8 (fr) 2009-07-16
WO2008073923A2 (fr) 2008-06-19
IL199161A0 (en) 2010-03-28
AU2007333110A1 (en) 2008-06-19
WO2008073923A3 (fr) 2008-12-11
EP2102342A2 (fr) 2009-09-23
EP2102341A2 (fr) 2009-09-23
WO2008085797A3 (fr) 2008-10-09
WO2008085797A2 (fr) 2008-07-17
AU2007342068A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
US20090175827A1 (en) miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
CA2671302A1 (fr) Genes et voies regules par miarn comme cibles d'intervention therapeutique
CN101627121A (zh) 作为治疗干预的靶标的miRNA调控基因和路径
US20090232893A1 (en) miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090163434A1 (en) miR-20 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20090227533A1 (en) miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20090192102A1 (en) miR-21 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090163435A1 (en) miR-200 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US8071562B2 (en) MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20090131356A1 (en) miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
EP2104737B1 (fr) Fonctions et cibles de microarn let-7
US20090192114A1 (en) miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20100305188A1 (en) Nucleic acid capable of regulating the proliferation of cell
US20090131354A1 (en) miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
Di Martino et al. miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review
EP2104736B1 (fr) Gènes et voies régulés par mir-126 comme cibles d'intervention thérapeutique
AU2007299873A1 (en) miR-143 regulated genes and pathways as targets for therapeutic intervention
Mo MicroRNA-21 Targets PDCD4 Expression in Retinoblastoma
Jiang et al. shRNA inhibits the expression of chicken telomerase reverse transcriptase in MDCC-MSB1 cells
حسینی اصل et al. RNA interference

Legal Events

Date Code Title Description
FZDE Discontinued